Zobrazeno 1 - 10
of 401
pro vyhledávání: ''
Publikováno v:
Cancer Investigation. 40:124-131
BACKGROUND Large Cell Neuroendocrine Carcinoma of the Lung (L-LCNEC) is a rare type of neuroendocrine lung cancer that is increasingly diagnosed. However, the optimal management regarding the advanced stage is unclear. The purpose of this article is
Publikováno v:
Cancer Investigation. 39:734-740
BACKGROUND The purpose of this study was to compare survival outcomes in patients with perineural invasion (PNI)-positive laryngeal squamous cell carcinoma (LSCC) and patients with PNI-negative LSCC. METHODS A total of 1,272 patients with LSCC, diagn
Autor:
Attalla F. El-kott, Nora A Farag, Nadia El-Menshawy, Hayam Fathi Ghazi, Doaa Atia, Eman Fawzi, Doaa A. Shahin, Mohamed Eissa, Nashwa K. Abousamra
Publikováno v:
Cancer Investigation. 39:777-782
OBJECTIVE Multiple myeloma is an incurable hematological malignancy. Currently, the use of proteasome inhibitors could be superior to chemotherapy-based regimen in the treatment of this disease. However, resistance to bortezomib combination therapy s
Publikováno v:
Cancer Investigation. 39:645-652
The aim of the study was to report long-term results of intensity-modulated radiotherapy for patients with T4 classification nasopharyngeal carcinoma (NPC). From September 2007 to January 2013, 155 patients were retrospectively analyzed. The estimate
Publikováno v:
Cancer Investigation. 39:597-606
Fourty-five breast cancer patients and 50 apparently healthy sex-matched controls from the University of Ilorin Teaching Hospital were enrolled in this study. Plasma D-dimer and fibrinogen were found to be significantly higher than controls; APTT was
Autor:
Beatriz Castelo, Jacobo Rogado, Paula Jiménez-Fonseca, Eva Martínez de Castro, Raquel Hernández, Oliver Higuera, Alberto Carmona-Bayonas, Ismael Ghanem, María del Mar Muñoz, Caterina Calderon
Publikováno v:
Cancer Investigation. 39:589-596
The aim of this study was to compare physicians' and patients' estimates of risk of relapse and toxicity. A prospective, cross-sectional, multicenter study including 735 patients with cancer and 29 oncologists. Physicians' appraisals of risk of relap
Autor:
Jianhua Feng, Kang Yu, Yisha Huang, Qianying Zhang, Yu Zhang, Yiyun Feng, Kanchun Dai, Deeksha Bhardwaj
Publikováno v:
Cancer Investigation. 39:550-558
This study aimed to examine the prognostic significance of peripheral absolute monocyte count (AMC) in combination with absolute lymphocyte count (ALC) at the time of relapse in a cohort of 57 patients with early relapsed (first complete remission12
Autor:
Kadir Eser, Pinar Saip, Erdem Cubukcu, Fuat Demirelli, Ozkan Alan, Zuleyha Calikusu, Aykut Bahceci, Ali Alkan, Hacer Demir, Mahmut Büyükşimşek, Cemile Karadeniz, Erhan Gokmen, Naziye Ak, Mehmet Bilici, Altay Aliyev, Turkkan Evrensel, Oznur Bal, Atakan Demir, Özge Keskin, Nilgün Yildirim, Saadettin Kilickap, Semra Paydas, Atike Gökçen Demiray, Kezban Nur Pilanci, Ali Gökyer, Perran Fulden Yumuk, Birol Yildiz, Duygu Ilke Cikman, Ismail Beypinar, Taner Korkmaz, Sinan Yavuz, Burcu Çakar, Erkan Arpaci, Gulsah Seydaoglu, Ferhat Ferhatoglu, Ahmet Z. Sahin, Gulcan Bulut, Serkan Degirmencioglu, Cengiz Karacin, Mutlu Dogan, Havva Yesil Cinkir, Kerem Okutur, Semiha Urvay, Deniz Işik, Melih Simsek, Osman Kostek, Meltem Baykara, Salim Basol Tekin, Deniz Yamac
Publikováno v:
Cancer Investigation. 39:473-481
Aim: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method: Retrospective analysis of T-DM1 results of human epidermal grow
Autor:
Kristina Tendl-Schulz, Maria Bernathova, Michael Seifert, Christian Pfeifer, Alexandra Fügerl, Sabine Danzinger
Publikováno v:
Cancer Investigation. 39:457-465
We analyzed the effect of anemia on tumor response of patients with primary invasive breast cancer (BC) receiving neoadjuvant chemotherapy (NACT). The patient collective was very homogenous; finally, 74 BC patients with identical medication and durat
Autor:
Keisuke Monji, Ario Takeuchi, Ryosuke Takahashi, Junichi Inokuchi, Satoshi Kobayashi, Masatoshi Eto, Takashi Matsumoto, Masaki Shiota, Asako Machidori, Akira Yokomizo, Eiji Kashiwagi, Ken ichiro Shiga, Takuya Yamashita
Publikováno v:
Cancer Investigation. 39:251-256
We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m2) betwee...